PT -期刊文章盟-西尔伯斯坦(Stephen盟Shashidhar古里AU -黎明Buse盟黎明马库斯AU -椎名极光AU -格雷琴Tietjen盟- > - AU -安德鲁Czeizel盟Richard Lipton TI -双氢麦角胺:回顾产妇在怀孕期间接触(P03.108) DP - 2013年2月12日TA -神经病学PG - P03.108 P03.108 VI - 80 IP - 7补充4099 - //www.ez-admanager.com/content/80/7_Supplement/P03.108.short 4100 - //www.ez-admanager.com/c首页ontent/80/7_Supplement/P03.108.full所以Neurology2013 2月12;80 AB -目的:评估潜在风险进行文献综述与母亲接触双氢麦角胺(她)怀孕期间。背景:怀孕风险类别药物分配给我们基于来自动物和人类研究的证据。当前配方的她和麦角胺有相同的怀孕风险类别(X),尽管她更少的血管和子宫的影响。设计/方法:MEDLINE / PubMed搜索进行了识别引用从1945年1月至2011年10月出版,描述胎儿与她在怀孕期间或麦角胺使用相关的结果。包括临床研究,病例报告/系列、数据库/回顾评论或研究,文章通过二次确定搜索相关文章和引用,包括主要作者。综述了研究设计、治疗干预措施和结果。结果:213个潜在的引文,11满足入选标准。Fetal outcome data for >350 infants with DHE exposure in utero did not show a statistically significant increased risk of major congenital malformations. An increased risk of prematurity, however, has been reported. Transient fetal bradycardia was also reported when DHE was used during labor. Increased miscarriage risk was possibly associated with high intravenous doses administered to induce labor.CONCLUSIONS: In this literature analysis, DHE use during pregnancy was not reported to be associated with a statistically significant risk of major congenital malformations. It was however associated with a higher risk of prematurity.Supported by: MAP Pharmaceuticals, Inc.Disclosure: Dr. Silberstein has received personal compensation for activities with Allergan, Amgen, Capnia, Coherex, Iroko Pharmaceuticals, Lilly, MAP, Medtronic, Neuralieve, NINDS, NuPathe, Pfizer, St. Jude Medical as an advisory board member and from Amgen, Nautiluss, Opti-Nose, and Zogenix as a consultant. Dr. Silberstein has received personal compensation in an editorial capacity for Current Pain and Headache Reports and Medlink as an advisory board member. Dr. Silbertsein has received research support from Allergan, BMS, Cumberland, Lilly, MAP, Merck, OptiNose, and St. Jude Medical. Dr. Kori has received personal compensation for activities with MAP Pharmaceuticals, Inc. Dr. Kori holds stock and/or stock options in MAP Pharmaceuticals, Inc. Dr. Kori has received research support from MAP Pharmaceuticals, Inc. Dr. Buse has received personal compensation for activities with Allergan as a scientific advisor. Dr. Buse has received research suprrot or has support pending from Allergan, ENDO, MAP, Nupathe and Merck to the National Headache Foundation. Dr. Marcus has received research support from Pfizer Inc, Merck & Co., Inc., and GlaxoSmithKline, Inc. Dr. Aurora has received personal compensation for activities with GlaxoSmithKline, Inc., Merck & Co., Inc., Ortho-McNeil, Allergan, Inc., MAP Pharmaceuticals, Kyowa, and Neuraleve. Dr. Aurora has received research support from Alexza, Allergan, Inc., GlaxoSmithKline, Inc., Merck, Pfizer, Inc., Ortho-McNeil, MAP pharmaceuticals, Takeda, and Neuraleve. Dr. Tietjen has received personal compensation for activities with MAPP. Dr. Tietjen holds stock and/or stock options in Johnson & Johnson and Stryker. Dr. Tietjen's institution received research support from Lundbeck Research USA, inc. Dr. Berard has received personal compensation for activities with MAP Pharmaceuticals. Dr. Berard has received research support from MAP Pharmaceuticals, CIHR, FRSQ, and NIH. Dr. Czeizel has nothing to disclose. Dr Lipton has received personal compensation for activities with Allergan, Inc., Boston Scientific, Bristol-Myers Squibb Company, Cognimed, Colucid, Eli Lilly & Company, eNeura Therapeutics, GlaxoSmithKline, Inc., MAP, Merck, Nautilus Neuroscience, Novartis, and NuPathe. Dr. Lipton holds stock and/or stock options in eNeura Therapeutics.Tuesday, March 19 2013, 2:00 pm-6:30 pm